OBJECTIVE: The aim was to determine whether three commonly used animal anaesthetics alter the magnitude of infarct limitation achieved with ischaemic preconditioning. METHODS: Eighty four anaesthetised non-preconditioned and preconditioned open chest rabbits underwent a 30 min coronary occlusion followed by 3 h reperfusion. Ischaemic preconditioning was achieved with 5 min coronary occlusion beginning 15 min before the 30 min coronary occlusion. The anaesthetics studied were: pentobarbitone (30 mg.kg-1 intravenously +30-50 mg.kg-1.h-1 intravenously), isoflurane (1.5-2.5% end expiratory), and ketamine/xylazine (cocktail of 67 mg ketamine and 6.7 mg xylazine.ml-1, 1 ml.kg-1 intramuscularly +0.3-1.3 ml.kg-1.h-1 intramuscularly). Area at risk was delineated with ZnCdS particles and infarction assessed with tetrazolium. RESULTS: There were no significant differences in area at risk, heart rate, arterial pressure, and temperature between non-preconditioned and preconditioned hearts. Although infarct size was not significantly different among non-preconditioned hearts for each anaesthetic regimen (p = NS), the magnitude of infarct limitation with preconditioning varied with the anaesthetic employed (decrease in infarct size from control values of 81%, 44%, and 33% for pentobarbitone, isoflurane and ketamine/xylazine, respectively, p = 0.0145 for comparison of the three magnitudes, two factor ANOVA). CONCLUSION: Anaesthetic regimens affect the degree of infarct size limitation seen with ischaemic preconditioning.
OBJECTIVE: The aim was to determine whether three commonly used animal anaesthetics alter the magnitude of infarct limitation achieved with ischaemic preconditioning. METHODS: Eighty four anaesthetised non-preconditioned and preconditioned open chest rabbits underwent a 30 min coronary occlusion followed by 3 h reperfusion. Ischaemic preconditioning was achieved with 5 min coronary occlusion beginning 15 min before the 30 min coronary occlusion. The anaesthetics studied were: pentobarbitone (30 mg.kg-1 intravenously +30-50 mg.kg-1.h-1 intravenously), isoflurane (1.5-2.5% end expiratory), and ketamine/xylazine (cocktail of 67 mg ketamine and 6.7 mg xylazine.ml-1, 1 ml.kg-1 intramuscularly +0.3-1.3 ml.kg-1.h-1 intramuscularly). Area at risk was delineated with ZnCdS particles and infarction assessed with tetrazolium. RESULTS: There were no significant differences in area at risk, heart rate, arterial pressure, and temperature between non-preconditioned and preconditioned hearts. Although infarct size was not significantly different among non-preconditioned hearts for each anaesthetic regimen (p = NS), the magnitude of infarct limitation with preconditioning varied with the anaesthetic employed (decrease in infarct size from control values of 81%, 44%, and 33% for pentobarbitone, isoflurane and ketamine/xylazine, respectively, p = 0.0145 for comparison of the three magnitudes, two factor ANOVA). CONCLUSION: Anaesthetic regimens affect the degree of infarct size limitation seen with ischaemic preconditioning.
Authors: Y Qiu; P Ping; X L Tang; S Manchikalapudi; A Rizvi; J Zhang; H Takano; W J Wu; S Teschner; R Bolli Journal: J Clin Invest Date: 1998-05-15 Impact factor: 14.808
Authors: Andreas Goetzenich; Nima Hatam; Stephanie Preuss; Ajay Moza; Christian Bleilevens; Anna B Roehl; Rüdiger Autschbach; Jürgen Bernhagen; Christian Stoppe Journal: Interact Cardiovasc Thorac Surg Date: 2013-12-18
Authors: Ruben C Sloan; Matthew Rosenbaum; Dorcas O'Rourke; Karen Oppelt; Chad R Frasier; Corinne A Waston; Amanda G Allan; David A Brown Journal: J Am Assoc Lab Anim Sci Date: 2011-05 Impact factor: 1.232
Authors: Leonid N Maslov; Yury B Lishmanov; Peter R Oeltgen; Eva I Barzakh; Andrey V Krylatov; Natalia V Naryzhnaya; Jian-Ming Pei; Stephen A Brown Journal: Acad Emerg Med Date: 2010-11 Impact factor: 3.451
Authors: David A Brown; Sharon L Hale; Christopher P Baines; Carlos L del Rio; Robert L Hamlin; Yukie Yueyama; Anusak Kijtawornrat; Steve T Yeh; Chad R Frasier; Luke M Stewart; Fatiha Moukdar; Saame Raza Shaikh; Kelsey H Fisher-Wellman; P Darrell Neufer; Robert A Kloner Journal: J Cardiovasc Pharmacol Ther Date: 2013-11-28 Impact factor: 2.457